Literature DB >> 21320562

Donor human leukocyte antigen specific antibodies predict development and define prognosis in transplant glomerulopathy.

Hooi Sian Eng1, Greg Bennett, Sean H Chang, Hannah Dent, Stephen P McDonald, Peter Bardy, Patrick Coghlan, Graeme R Russ, P Toby H Coates.   

Abstract

The pathogenesis of transplant glomerulopathy (TG) remains unclear, with evidence of human leukocyte antigen (HLA) antibodies as important contributors to the disease. We studied the risk factors and the associations of HLA antibodies in the development of TG. Sixty-one cases with morphologic features of TG were identified and compared with contemporaneous matched patients (without TG) from a 17-year period, all undergoing renal biopsy in a single center. Univariate risk factors for TG were previous glomerulitis [odds ratio (OR) 3.3, 95% confidence interval (95% CI) [1.2-9.4], p = 0.025), delayed graft function (OR 2.3 [1.0-5.1], p = 0.042), HLA class I presensitization defined by Luminex solid-phase immunoassays (OR 5.0 [2.3-11.0]. p < 0.001), and de novo posttransplant development of donor HLA specific antibody (DSA) (OR 4.7 [1.7-13.2], p = 0.002). Only DSA remained significantly associated with TG after adjustment (OR 3.8 [1.1-12.9], p = 0.032). DSA was detected in >50% of TG patients, suggesting HLA antibodies play a critical role in TG pathogenesis. TG patients with DSA had increased risk of graft loss (median graft survival 4.4-5.2 years), whereas patients with morphologic features of TG without DSA had similar graft survival compared with the non-TG group (median graft survival 15 years). Thus, DSA is a useful predictor for graft failure in TG patients. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21320562     DOI: 10.1016/j.humimm.2011.02.002

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

1.  Persistence of recipient human leucocyte antigen (HLA) antibodies and production of donor HLA antibodies following reduced intensity allogeneic haematopoietic stem cell transplantation.

Authors:  Ross M Fasano; Ewelina Mamcarz; Sharon Adams; Theresa Donohue Jerussi; Kyoko Sugimoto; Xin Tian; Willy A Flegel; Richard W Childs
Journal:  Br J Haematol       Date:  2014-04-18       Impact factor: 6.998

Review 2.  B cells in transplant tolerance and rejection: friends or foes?

Authors:  Robin Schmitz; Zachary W Fitch; Paul M Schroder; Ashley Y Choi; Annette M Jackson; Stuart J Knechtle; Jean Kwun
Journal:  Transpl Int       Date:  2020-01       Impact factor: 3.782

3.  Integration of humoral and cellular HLA-specific immune responses in cord blood allograft rejection.

Authors:  R Hanajiri; M Murata; K Sugimoto; M Murase; R Sakemura; T Goto; K Watanabe; N Imahashi; S Terakura; H Ohashi; Y Akatsuka; S Kurahashi; K Miyamura; H Kiyoi; T Nishida; T Naoe
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

4.  Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.

Authors:  Corey Cutler; Haesook T Kim; Lixian Sun; Doreen Sese; Brett Glotzbecker; Philippe Armand; John Koreth; Vincent Ho; Edwin Alyea; Karen Ballen; Jerome Ritz; Robert J Soiffer; Edgar Milford; Joseph H Antin
Journal:  Blood       Date:  2011-09-22       Impact factor: 22.113

5.  Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection.

Authors:  Nicholas J Steers; Yifu Li; Zahida Drace; Justin A D'Addario; Clara Fischman; Lili Liu; Katherine Xu; Young-Ji Na; Y Dana Neugut; Jun Y Zhang; Roel Sterken; Olivia Balderes; Drew Bradbury; Nilgun Ozturk; Fatih Ozay; Sanya Goswami; Karla Mehl; Jaclyn Wold; Fatima Z Jelloul; Mersedeh Rohanizadegan; Christopher E Gillies; Elena-Rodica M Vasilescu; George Vlad; Yi-An Ko; Sumit Mohan; Jai Radhakrishnan; David J Cohen; Lloyd E Ratner; Francesco Scolari; Katalin Susztak; Matthew G Sampson; Silvia Deaglio; Yasar Caliskan; Jonathan Barasch; Aisling E Courtney; Alexander P Maxwell; Amy J McKnight; Iuliana Ionita-Laza; Stephan J L Bakker; Harold Snieder; Martin H de Borst; Vivette D'Agati; Antonio Amoroso; Ali G Gharavi; Krzysztof Kiryluk
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245

6.  Persistence of anti-HLA antibody after cord blood transplantation engraftment in acute myelogenous leukemia: a potential marker of minimal residual disease, but not a significant factor in secondary humoral engraftment failure.

Authors:  Takumi Hoshino; Satoru Takada; Kenichi Tahara; Hiroaki Shimizu; Nahoko Hatsumi; Shuichi Miyawaki; Tohru Sakura
Journal:  Int J Hematol       Date:  2013-03-03       Impact factor: 2.490

7.  Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy.

Authors:  Pallavi Patri; Surya V Seshan; Marie Matignon; Dominique Desvaux; John R Lee; Jun Lee; Darshana M Dadhania; David Serur; Philippe Grimbert; Choli Hartono; Thangamani Muthukumar
Journal:  Kidney Int       Date:  2016-02       Impact factor: 10.612

8.  Association between transplant glomerulopathy and graft outcomes following kidney transplantation: A meta-analysis.

Authors:  Gábor Kovács; Giovanna Devercelli; Tamás Zelei; Ishan Hirji; Zoltán Vokó; Paul A Keown
Journal:  PLoS One       Date:  2020-04-28       Impact factor: 3.240

9.  Endothelin A Receptors Expressed in Glomeruli of Renal Transplant Patients May Be Associated with Antibody-Mediated Rejection.

Authors:  Katarzyna Nowańska; Mirosław Banasik; Piotr Donizy; Katarzyna Kościelska-Kasprzak; Sławomir Zmonarski; Krzysztof Letachowicz; Dorota Kamińska; Oktawia Mazanowska; Hanna Augustyniak-Bartosik; Andrzej Tukiendorf; Anna Chudiak; Tomasz Dawiskiba; Agnieszka Hałoń; Magdalena Krajewska
Journal:  J Clin Med       Date:  2021-01-22       Impact factor: 4.241

Review 10.  Transplant glomerulopathy: the interaction of HLA antibodies and endothelium.

Authors:  William Hanf; Claudine S Bonder; P Toby H Coates
Journal:  J Immunol Res       Date:  2014-03-09       Impact factor: 4.818

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.